Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 15,969,356 | 13,046,433 | 15,661,608 | 20,139,699 | 19,131,206 | 83,948,302 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 15,969,356 | 13,046,433 | 15,661,608 | 20,139,699 | 19,131,206 | 83,948,302 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 8,102,833 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 75,845,469 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 15,969,356 | 13,046,433 | 15,661,608 | 20,139,699 | 19,131,206 | 83,948,302 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 1,755,392 | 2,417,283 | 3,252,026 | 1,704,321 | 1,599,807 | 10,728,829 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 371,093 | 219,523 | 8,150 | 160,156 | 758,922 | |
| 11 | Total support. Add lines 7 through 10 | 95,436,053 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2022 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2022 |
(iii) Distributable Amount for 2022 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2022 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2022 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2022: | ||||
| a From 2017....... | ||||
| b From 2018....... | ||||
| c From 2019....... | ||||
| d From 2020....... | ||||
| e From 2021....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2022 distributable amount | ||||
|
i
Carryover from 2017 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2022 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2022 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2022, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2022. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2023. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2018..... | ||||
| b Excess from 2019..... | ||||
| c Excess from 2020..... | ||||
| d Excess from 2021..... | ||||
| e Excess from 2022..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990, PART III, LINE 4A | RESEARCH PROGRAM $20,863,817 GRANTS $19,379,059 THE LUSTGARTEN FOUNDATION'S MISSION IS TO ADVANCE THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. 2023 MARKED THE FOUNDATION'S 25TH ANNIVERSARY OF DRIVING PIONEERING PANCREATIC CANCER RESEARCH BREAKTHROUGHS, ACCELERATING PROGRESS FASTER THAN EVER BEFORE AND PROVIDING A MORE HOPEFUL FUTURE FOR ALL PATIENTS. IN 2023, THE FOUNDATION AWARDED 17 NEW GRANTS TOTALING UP TO $23 MILLION TO RESEARCHERS AT 13 LEADING INSTITUTIONS. OF THE NEW GRANTS AWARDED, 60% SUPPORT DRUG DEVELOPMENT PROJECTS; 24% SUPPORT EARLY DETECTION AND INTERCEPTION EFFORTS; AND 16% SUPPORT PERSONALIZED MEDICINE STUDIES. WITH THE ADDITION OF THESE NEW GRANTS, THE FOUNDATION NOW SUPPORTS 59 ACTIVE GRANTS ACROSS 30 INSTITUTIONS REPRESENTING ALMOST $45 MILLION OF COMMITTED FUNDING. THE CUMULATIVE TOTAL THE LUSTGARTEN FOUNDATION INVESTED IN RESEARCH THROUGH JUNE 2023 IS $270 MILLION. DURING FY23, MAJOR LUSTGARTEN-FUNDED INITIATIVES INCLUDED: - THE LUSTGARTEN FOUNDATION-SWIM ACROSS AMERICA-AACR EARLY DETECTION RESEARCH GRANT WAS AWARDED TO AJAY GOEL, PHD, PROFESSOR AND CHAIR, DEPARTMENT OF MOLECULAR DIAGNOSTICS AND EXPERIMENTAL THERAPEUTICS, BECK RESEARCH INSTITUTE OF THE CITY OF HOPE, FOR HIS STUDY "A CIRCULATING EPIGENETIC SIGNATURE FOR EARLY DETECTION OF PANCREATIC CANCER." THIS NEW PARTNERSHIP WITH SWIM ACROSS AMERICA WILL STIMULATE INNOVATIVE WORK IN THE EARLY DETECTION OF PANCREATIC CANCER AND BRING NEW TALENT TO THE FIELD. - ELLIOT FISHMAN, MD, DIRECTOR, DIAGNOSTIC IMAGING AND BODY CT, AND PROFESSOR OF RADIOLOGY AND RADIOLOGICAL SCIENCE, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, AND ALAN YUILLE, PHD, BLOOMBERG DISTINGUISHED PROFESSOR, DEPARTMENT OF COMPUTER SCIENCE, JOHNS HOPKINS WHITING SCHOOL OF ENGINEERING, RECEIVED GRANTS FOR THEIR CONTINUING PANCREATIC CANCER EARLY DETECTION WORK. THEIR PROJECTS BUILD ON THE SUCCESS OF THE FELIX PROGRAM, FUNDED BY LUSTGARTEN SINCE 2016. THE FELIX PROGRAM USES DATA FROM THOUSANDS OF CT SCANS TO TEACH COMPUTERS TO DETECT TUMORS SMALL ENOUGH TO BE MISSED BY EVEN THE MOST EXPERIENCED RADIOLOGISTS. DR. FISHMAN'S STUDY, ENTITLED "FELIX 2.0: THE INTEGRATION OF AI INTO THE EARLY DETECTION AND MANAGEMENT OF PANCREATIC CANCER WITH NOVEL AI ALGORITHMS AND ADVANCED DATA ANALYSIS," WILL BE DRIVEN BY HIS COLLABORATION WITH MICROSOFT AI FOR GOOD TO LEVERAGE ADDITIONAL RESOURCES AND EXPERTISE TO FURTHER REFINE AUTOMATED DETECTION TOOLS FOR CT SCANS. HE WILL ALSO DEVELOP NOVEL TOOLS TO SUPPORT PHYSICIANS IN MANAGING PATIENTS WITH PRE-CANCEROUS CYSTS. DR. YUILLE'S STUDY, ENTITLED "FELIX CIVITAS," INVOLVES RESEARCHERS WORKING TO ENSURE THE AI ALGORITHMS WILL ASSIST DOCTORS AND RADIOLOGISTS IN A WAY THAT ALIGNS BEST WITH THEIR NEEDS AND PRIORITIES. - THE LUSTGARTEN ADVANCING BREAKTHROUGH SCIENCE (LABS) PROGRAM, A HALLMARK OF THE FOUNDATION'S UNIQUE RESEARCH STRATEGY, HAD AN ESPECIALLY MOMENTOUS YEAR, WITH THREE OUT OF THE SIX DEDICATED LABORATORIES UP FOR RENEWAL. AFTER RIGOROUS REVIEW, LUSTGARTEN CONTINUED FUNDING FOR ALL THREE LABS, LOCATED AT COLD SPRING HARBOR LABORATORY (LED BY DAVID TUVESON, MD, PHD), MASSACHUSETTS INSTITUTE OF TECHNOLOGY (LED BY TYLER JACKS, PHD), AND DANA-FARBER CANCER INSTITUTE (LED BY BRIAN WOLPIN, MD, MPH). THE LABS PROGRAM PROVIDES LONG-TERM FUNDING TO PROMOTE THE DEVELOPMENT OF INNOVATIVE IDEAS AND SPEED THE PACE OF DISCOVERY BY INCENTIVIZING INTERDISCIPLINARY TEAM SCIENCE, INCLUDING GROUPS WITH COMPLEMENTARY EXPERTISE ACROSS THE PIPELINE FROM TARGET DISCOVERY AND VALIDATION TO PRECLINICAL DEVELOPMENT AND CLINICAL TESTING. - THE ORGANOIDS FOR PERSONALIZED THERAPEUTICS PROGRAM WAS APPROVED FOR EXPANSION INTO THE FOURTH PHASE. LED BY DAVID TUVESON, MD, PHD AT COLD SPRING HARBOR LABORATORY, ORGANOID PERSONALIZED THERAPEUTICS PHASE 4 PROJECT-OPT4" BUILDS ON PREVIOUS PHASES AND SUCCESSES, TO LEVERAGE PATIENT-DERIVED ORGANOID MODELS FOR THE STUDY OF PANCREATIC CANCER AND WILL ADVANCE THE DEVELOPMENT OF EARLY DETECTION TOOLS AND THERAPEUTIC OPTIONS. - THE LUSTGARTEN FOUNDATION-AACR CAREER DEVELOPMENT AWARDS HONORING RUTH BADER GINSBURG AND JOHN ROBERT LEWIS WERE GIVEN TO ASHLEY KIEMEN, PHD, ASSISTANT PROFESSOR OF ONCOLOGY AND PATHOLOGY, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, FOR HER STUDY "3D MORPHOLOGICAL ANALYSIS OF HUMAN PANCREATIC CANCER LIVER METASTASES, AND CHRISTINA FERRER, PHD, ASSISTANT PROFESSOR OF PHARMACOLOGY, UNIVERSITY OF MARYLAND, BALTIMORE, FOR HER STUDY "METASTASIS-INITIATING CELLS IN PANCREATIC CANCER." THESE AWARDS FOSTER AND GROW THE NUMBER OF EARLY-CAREER WOMEN AND UNDERREPRESENTED SCIENTISTS WORKING IN PANCREATIC CANCER RESEARCH AND HONOR THE LIVES AND LEGACIES OF TWO ICONIC AMERICANS LOST TO PANCREATIC CANCER. THE AWARDS SUPPORT TRAILBLAZING INVESTIGATORS COMMITTED TO INCREASING THE UNDERSTANDING AND TREATMENT OF PANCREATIC CANCER. |
| FORM 990, PART III, LINE 4A | - THE LUSTGARTEN EQUITY, ACCESSIBILITY, AND DIVERSITY (LEAD) GRANTS WERE PRESENTED TO KARYN GOODMAN, MD, MS, VICE CHAIR OF RADIATION ONCOLOGY AND ASSOCIATE DIRECTOR OF CLINICAL RESEARCH AT TISCH CANCER INSTITUTE, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, FOR HER STUDY "NAVIGATING PANCREATIC CANCER MULTIDISCIPLINARY CARE TO ADDRESS CULTURAL AND LANGUAGE BARRIERS TO CLINICAL TRIAL ENROLLMENT AMONG MANDARIN AND SPANISH SPEAKING PATIENTS WITH PANCREATIC CANCER, AND REBECCA SNYDER, MD, MPH, ASSOCIATE PROFESSOR IN THE DEPARTMENTS OF SURGICAL ONCOLOGY AND HEALTH SERVICES RESEARCH AT THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, FOR HER STUDY ENTITLED "IMPACT DIVERSITY: AN INTEGRATED MULTI-LEVEL PLAN TO ADDRESS CLINICAL TRIAL DIVERSITY." THE LEAD GRANTS WERE CREATED TO INCREASE THE RECRUITMENT AND RETENTION OF UNDERREPRESENTED GROUPS IN PANCREATIC CANCER CLINICAL TRIALS. - THE INNOVATION AND COLLABORATION PROGRAM GRANTS WERE AWARDED TO KACPER ROGALA, DPHIL, MRES, ASSISTANT PROFESSOR OF STRUCTURAL BIOLOGY AND OF CHEMICAL AND SYSTEMS BIOLOGY, STANFORD UNIVERSITY SCHOOL OF MEDICINE, FOR HIS STUDY "ESTABLISHING CHOLINE TRANSPORT AS SELECTIVE VULNERABILITY OF PANCREATIC CANCERS, AND DAVID KASHATUS, PHD, ASSOCIATE PROFESSOR, MICROBIOLOGY, IMMUNOLOGY, AND CANCER BIOLOGY, UNIVERSITY OF VIRGINIA, FOR HIS STUDY "THE ROLE OF LIPID DROPLETS IN PANCREATIC CANCER METASTASIS." THIS PROGRAM PROVIDES SEED FUNDING FOR HIGHLY INNOVATIVE RESEARCH PROJECTS WITH SIGNIFICANT POTENTIAL TO ACCELERATE THE LUSTGARTEN FOUNDATION'S MISSION TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. - DR. ROBERT F. VIZZA LUSTGARTEN CLINICAL ACCELERATOR INITIATIVE (CAI) GRANTS WERE AWARDED TO DAFNA BAR-SAGI, PHD, EXECUTIVE VICE PRESIDENT, VICE DEAN FOR SCIENCE, AND CHIEF SCIENTIFIC OFFICER, NYU LANGONE HEALTH, FOR HER STUDY "EVALUATION OF THE MECHANISM AND EFFICACY OF IL-15 SUPERAGONIST-BASED NEOADJUVANT CHEMO-IMMUNOTHERAPY FOR PANCREATIC CANCER;" MICHAEL PISHVAIAN, MD, PHD, DIRECTOR OF GASTROINTESTINAL, DEVELOPMENTAL THERAPEUTICS AND CLINICAL RESEARCH PROGRAMS ASSOCIATE PROFESSOR OF ONCOLOGY, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, FOR HIS STUDY "A PHASE II TRIAL OF OLAPARIB, PEMBROLIZUMAB, AND LENVATINIB AS SECOND-LINE THERAPY FOR BRCA1, BRCA2, OR PALB2-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA; AND PETER ALLEN, MD, CHIEF, DIVISION OF SURGICAL ONCOLOGY, DUKE UNIVERSITY SCHOOL OF MEDICINE, FOR HIS STUDY "A WINDOW-OF-OPPORTUNITY TRIAL USING NEOADJUVANT HEPATIC ARTERY CHEMOTHERAPY FOR PATIENTS WITH LOCALIZED PANCREAS CANCER." - THE CAI REDUCES THE TIME FROM CLINICAL TRIAL CONCEPT TO LAUNCH USING A LUSTGARTEN-DEVELOPED PROCESS BASED ON THE BEST AVAILABLE SCIENCE AND EMPLOYING INNOVATIVE BIOMARKERS. WITH THREE NEW TRIALS ADDED THIS YEAR, THERE ARE NOW SEVEN TRIALS SUPPORTED THROUGH THIS INNOVATIVE PROGRAM. - TO MAXIMIZE THE VALUE OF THE CAI STUDIES, THE LUSTGARTEN FOUNDATION BEGAN DEVELOPING THE LUSTGARTEN UNITED CLINICAL INFORMATION DATABASE (LUCID) TO HOUSE THE CHARACTERISTICS OF PATIENTS ACROSS STUDIES AND LINK THEM TO PATIENT OUTCOMES. BY PROVIDING A CENTRALIZED PLATFORM FOR DATA SHARING AND ANALYSIS, LUCID PROMOTES COLLABORATION BETWEEN RESEARCHERS, LEADING TO FASTER RESEARCH ADVANCEMENTS. ADDITIONALLY, LUCID WILL HELP RESEARCHERS IDENTIFY NEW TREATMENT APPROACHES AND BIOMARKERS AND UNDERSTAND DISEASE HETEROGENEITY AND PATIENT SUBGROUPS, DETERMINING WAYS TO MATCH THE RIGHT PATIENTS TO THE RIGHT TREATMENTS AND IMPROVE OUTCOMES. - IN 2023, LUSTGARTEN CONTINUED OUR COLLABORATIONS WITH ORGANIZATIONS INCLUDING STAND UP TO CANCER, AMERICAN ASSOCIATION FOR CANCER RESEARCH, AND BREAK THROUGH CANCER, AND FORMED A NEW PARTNERSHIP WITH SWIM ACROSS AMERICA. THROUGH THESE PARTNERSHIPS, LUSTGARTEN BRINGS FOCUS AND STRATEGY TO PANCREATIC CANCER RESEARCH AND MAXIMIZES OUR COLLECTIVE FINANCIAL INVESTMENT SO WE CAN FUND THE MOST HIGH-RISK, HIGH-REWARD SCIENCE. |
| FORM 990, PART III, LINE 4B | PUBLIC EDUCATION AND INFORMATION PROGRAM $1,374,374 THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS, AND TRANSFORMING PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS, AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. 100% OF ALL DONATIONS FUEL THE RESEARCH TO ADVANCE UNDERSTANDING OF THIS COMPLEX, DEVASTATING AND UNDERFUNDED CANCER. THE LUSTGARTEN FOUNDATION CREATED, PRINTED, AND DISTRIBUTED MATERIALS TO UPDATE PATIENTS, CAREGIVERS, SURVIVORS, DONORS, VOLUNTEERS, WALK AND EVENT LEADERS AND CORPORATE SPONSORS ON RESEARCH DEVELOPMENTS, FOUNDATION MILESTONES, AND WALKS/EVENTS. MATERIALS INCLUDED: - LUSTGARTENLIVE! SERIES OF RESEARCH-FOCUSED, INTERACTIVE WEBINARS - PROGRESS & PROMISE NEWSLETTER - ANNUAL REPORT - RESEARCH MILESTONES UPDATE - MONTHLY E-NEWSLETTER WITH VIDEO INTRODUCTION - DIRECT MAIL AND ACQUISITION MAIL PIECES - MONTHLY PANCCHATS ON TWITTER, BRINGING EXPERTS AND PATIENTS TOGETHER TO DISCUSS TOPICS PERTINENT TO THE PANCREATIC CANCER COMMUNITY - INCREASED FOCUS ON VIDEO WE ALSO CONTINUED DISTRIBUTING OUR NAVIGATING PANCREATIC CANCER: A GUIDE FOR PATIENTS & CAREGIVERS HANDBOOK, CONTAINING INFORMATION ON MANAGING A PANCREATIC CANCER DIAGNOSIS AND TREATING THE DISEASE. THE BOOK AND MANY OF THE MATERIALS NOTED ABOVE ARE ACCESSIBLE AT WWW.LUSTGARTEN.ORG. |
| FORM 990, PART III, LINE 4C | PROFESSIONAL EDUCATION PROGRAM $804,224 PROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SENIOR LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH FUNDED SCIENTISTS AND DIRECTORS OF THE LABS PROGRAM SITES AND COLLABORATING ORGANIZATIONS, AS WELL AS ATTENDING/PRESENTING AT SCIENTIFIC MEETINGS FOR ORGANIZATIONS INCLUDING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) AND STAND UP TO CANCER (SU2C). THE FOUNDATION BEGAN PREPARING FOR ITS ROLE AS A LEAD SPONSOR FOR THE AACR SPECIAL MEETING ON PANCREATIC CANCER HELD IN SEPTEMBER 2023. IN CONJUNCTION WITH THE UNIVERSITY OF BOLOGNA IN ITALY, ON APRIL 3, 2023, LUSTGARTEN HELD A SYMPOSIUM ENTITLED PANCREATIC CANCER: THE COMMITMENT OF BREAKTHROUGH SCIENCE FOR A BETTER PROGNOSIS FEATURING THE FOUNDATION'S CHIEF MEDICAL ADVISOR, ELIZABETH JAFFEE, MD, AND SEVERAL OTHER EXPERTS INVOLVED IN PANCREATIC CANCER RESEARCH. ADDITIONALLY, THE FOUNDATION STARTED PLANNING FOR ITS ANNUAL SCIENTIFIC MEETING FOR THE SCIENTIFIC ADVISORY BOARD AND SELECT RESEARCHERS IN THE BANBURY CENTER AT COLD SPRING HARBOR LABORATORY, HELD IN OCTOBER 2023. THE FOUNDATION STARTED ORGANIZING ITS INAUGURAL SEEING BEYOND SCIENTIFIC SYMPOSIUM, HELD IN NEW YORK CITY IN NOVEMBER 2023, TO SHOWCASE THE GROUNDBREAKING RESEARCH OF SEVERAL LUSTGARTEN-FUNDED RESEARCHERS AND TO AWARD BERT VOGELSTEIN, MD, WITH THE INAUGURAL LUSTGARTEN LUMINARY AWARD FOR HIS SIGNIFICANT CONTRIBUTIONS TO PANCREATIC CANCER RESEARCH. THESE MEETINGS HELP FOSTER COLLABORATION AND A BETTER UNDERSTANDING OF GLOBAL DEVELOPMENTS IN PANCREATIC CANCER RESEARCH AND PROGRESS/TRENDS TO HELP SHAPE THE FOUNDATION'S ANNUAL RESEARCH PROGRAM AND LONG-TERM STRATEGIC GOALS. |
| FORM 990, PART VI, SECTION A, LINE 2 | CHARLES F. DOLAN, JAMES L. DOLAN AND QUENTIN F. DOLAN - FAMILY AND BUSINESS RELATIONSHIP. MARCIA LUSTGARTEN, ANDREW LUSTGARTEN AND JESSICA LUSTGARTEN COURTEMANCHE - FAMILY RELATIONSHIP. ANDREW LUSTGARTEN, JAMES L. DOLAN, PHILIP D'AMBROSIO, AND QUENTIN F. DOLAN - BUSINESS RELATIONSHIP. |
| FORM 990, PART VI, SECTION B, LINE 11B | FORM 990 IS REVIEWED BY THE PRESIDENT FOR ACCURACY AND REASONABLENESS PRIOR TO SUBMISSION TO THE IRS. ADDITIONALLY A COMPLETE COPY OF THE FINAL RETURN IS PROVIDED TO ALL VOTING BOARD MEMBERS PRIOR TO FILING WITH THE IRS. |
| FORM 990, PART VI, SECTION B, LINE 12C | THE ORGANIZATION HAS A WRITTEN CONFLICT OF INTEREST POLICY. THE WRITTEN POLICY REQUIRES ANNUAL DISCLOSURES BY ALL MEMBERS OF THE BOARD OF DIRECTORS, OFFICERS, AND KEY PERSONS OF ANY INTEREST THAT COULD GIVE RISE TO CONFLICT. THE ORGANIZATION REGULARLY AND CONSISTENTLY MONITORS AND ENFORCES THE COMPLIANCE OF THE CONFLICT OF INTEREST POLICY. IN THE INSTANCE WHERE A DIRECTOR HAS A CONFLICT, THEY ARE ASKED BY THE BOARD CHAIR TO RECUSE THEMSELVES FROM DELIBERATIONS, DECISIONS AND THE VOTE. |
| FORM 990, PART VI, SECTION B, LINE 15 | COMPENSATION FOR BOTH THE CHIEF EXECUTIVE OFFICER AND THE PRESIDENT WAS REVIEWED AND APPROVED BY THE INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS IN 2021, AND IT WAS RECONFIRMED IN MAY 2023. THE REVIEW WAS UNDERTAKEN BY A THIRD-PARTY HUMAN RESOURCES CONSULTANT AND INCLUDED THE USE OF COMPARABILITY DATA WHICH WAS CONTEMPORANEOUSLY DOCUMENTED. |
| FORM 990, PART VI, SECTION C, LINE 19 | AUDITED FINANCIAL STATEMENTS ARE MADE AVAILABLE ON THE ORGANIZATION'S WEBSITE. IN ADDITION, GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND AUDITED FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. |
| Software ID: | |
| Software Version: |